NEOPLASMS

This was a first-in-human study to test the safety and find the right dose of a new oral drug, JNJ-64619178, for people with advanced cancers that have not responded to other treatments. It involved 114 adults with specific advanced solid tumors, non-Hodgkin lymphoma, or a type o…

This was a first-in-human study to test the safety and early signs of effectiveness of a new drug called MK-4830. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 470 people with various advanced solid tumors that had stopped responding to s…

This early-stage trial tested a new drug called BI 754091 (ezabenlimab) in 110 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest and most effective dose by carefully monitoring side effects. Researchers also…

This early-stage study tested a new oral drug called TdCyd in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug works in the body. Researchers hoped the drug might slow tumor growth b…

This early-stage study aimed to find safe doses for several different combinations of cancer drugs in patients with advanced or metastatic solid tumors, including lung cancer. The 60 participants were divided into groups to test combinations of chemotherapy, immunotherapy, and ta…

This early-stage study tested a new cancer pill called brigimadlin in adults with advanced solid tumors that had spread or couldn't be treated with standard options. Researchers aimed to find the highest safe dose patients could tolerate, then used that dose to see if the medicat…

This early-stage study tested the safety of combining two cancer drugs, bortezomib and clofarabine, in adults with advanced solid tumors, lymphomas, or blood disorders that had stopped responding to standard treatments. The main goal was to find the highest dose patients could to…

This first-in-human study tested the safety and dosing of a new experimental drug called MK-4464, both alone and combined with an existing immunotherapy (pembrolizumab). It involved 64 adults with advanced solid tumors that had spread and who had run out of standard treatment opt…

This early-phase study tested a new type of cell therapy called RD13-02 in a small group of patients with aggressive blood cancers that had returned or not responded to standard treatments. The main goals were to check if the treatment was safe and to see how the modified immune …

This study tested a new oral drug called pelabresib for people with advanced blood cancers like myelofibrosis. The first part aimed to find a safe dose. The second part tested if pelabresib, given alone or with another drug (ruxolitinib), could shrink enlarged spleens, reduce the…

This early-stage study tested a combination of two immunotherapy drugs (BI 754111 and BI 754091) in adults with advanced solid tumors, including non-small cell lung cancer. The first goal was to find the safest highest dose. The second goal was to see if this combination could sh…

This first-in-human study tested a new oral medication called MRX-2843 in adults with advanced solid tumors that had returned or stopped responding to standard treatments. The main goals were to find the highest safe dose and understand how the drug moves through the body. Resear…

This early-stage study tested a new two-part radioactive drug for people with advanced solid tumors. First, a scanning agent identified tumors with a specific marker. Then, a therapeutic radioactive version was given to try to treat those tumors. The main goals were to check safe…

This early-stage study tested a new drug, JNJ-70218902, in men with advanced prostate cancer that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body handles the drug. The drug works by guiding the patient's own immune cells…

This first-in-human study tested the safety and early effectiveness of a new drug called vibostolimab. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 474 adults with advanced solid tumors that had stopped responding to other treatments. Th…

This was the first human study of an experimental cancer drug called LY3039478. Researchers tested it in 247 patients with advanced or metastatic cancer to find the highest dose that could be given safely. The study also looked for early signs that the drug might help shrink tumo…

This early-stage study tested a new combination of two drugs, BI 836880 and ezabenlimab, in adults with advanced non-small cell lung cancer and other solid tumors. The first part aimed to find the safest dose. The second part then used that dose to see if the treatment could shri…

This early-phase study tested two new drugs, BI 754091 and BI 754111, in Asian patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest and most effective doses of the drugs, both alone and in combination, and …

This was the first study in humans to test a new cancer drug called BI 836880. It involved 29 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of the drug and understand how the body handles it…

This was an early safety study to test a new cancer drug called BI 836880 in people with advanced solid tumors. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers gave the drug weekly to 24 patients and closely monitored th…

This small pilot study tested whether a 3-month digital program could help young adult cancer survivors become more active and eat healthier. The program used a smartphone app, lessons, and optional features like text messages and simplified food tracking. Researchers measured if…

This study tested a combination of two cancer drugs, brigimadlin and ezabenlimab, in adults with advanced solid tumors that had stopped responding to standard treatments. The first part aimed to find the highest safe dose of the drug combination. The second part aimed to see if t…

This early-stage trial tested whether two experimental drugs, FdCyd and THU, could be safely given as pills to people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest dose patients could tolerate without severe s…

This study tested if two new, advanced imaging scans could find prostate cancers that a standard MRI scan might miss in patients planning for a targeted therapy or surgery. The goal was to create a more accurate 'map' of the cancer to help guide treatment decisions. Researchers c…

This study tested a new device called PointCheck, which uses a camera to check for dangerously low white blood cell counts in cancer patients receiving chemotherapy. The goal was to see if the device was easy and safe to use, and to get an early idea of how well its readings matc…

This study tested whether a program where Chinese-speaking cancer patients and survivors write or record their thoughts about their experience is helpful and culturally appropriate. For four weeks, 60 participants reflected on their cancer journey and then wrote an anonymous lett…

This study tested whether a smartphone app could help cancer patients better track and report the side effects of their treatment. Over 200 patients starting chemotherapy or radiation used the app to log symptoms, which were then shared with their care team. Researchers wanted to…

This study tested whether a 12-week physical therapy program, delivered partly in-person and partly online, is practical and acceptable for children with acute lymphoblastic leukemia. The goal was to help kids manage the muscle and bone side effects of cancer treatment. Researche…

This study tested whether having a financial navigator could help cancer patients manage the high costs of treatment and reduce their financial stress. It involved 258 patients from both rural and non-rural clinics in North Carolina who were struggling with treatment expenses. Pa…

This study tested whether smartphones and smartwatches could be used to reliably measure symptoms like fatigue and changes in activity in cancer patients. Researchers enrolled 49 adults with various cancers who were already receiving treatment. They used iPhones and Apple Watches…

This study aimed to understand why some people with cancer also develop a condition called immune thrombocytopenia (ITP), which causes dangerously low platelet counts and bleeding risk. Researchers looked back at the medical records of 33 adult patients who had both ITP and cance…

This early-stage study tested two experimental cancer drugs—BI 836880 alone and combined with BI 754091—in 21 Japanese patients with advanced solid tumors. The main goal was to find the highest safe doses for future research, not to treat cancer. Researchers carefully monitored h…

This study aimed to better understand and measure the risk of dangerous blood clots in people with cancer. Researchers followed 700 hospitalized cancer patients to see how often clots occurred, especially in those already taking blood-thinning medications. The goal was to gather …

This study explored whether artificial intelligence (AI) could be trained to detect and classify pain in cancer patients by analyzing their facial expressions and voice patterns. Researchers enrolled 83 people aged 12 and older who were undergoing cancer treatment. Over three mon…